Cargando…
Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640901/ https://www.ncbi.nlm.nih.gov/pubmed/33195736 http://dx.doi.org/10.18632/oncoscience.514 |
| _version_ | 1783605842502746112 |
|---|---|
| author | Webster, Emily M. Zeybek, Burak Tymon-Rosario, Joan Santin, Alessandro D. |
| author_facet | Webster, Emily M. Zeybek, Burak Tymon-Rosario, Joan Santin, Alessandro D. |
| author_sort | Webster, Emily M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7640901 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76409012020-11-13 Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer Webster, Emily M. Zeybek, Burak Tymon-Rosario, Joan Santin, Alessandro D. Oncoscience Research Perspective Impact Journals LLC 2020-06-08 /pmc/articles/PMC7640901/ /pubmed/33195736 http://dx.doi.org/10.18632/oncoscience.514 Text en Copyright: © 2020 Webster et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Research Perspective Webster, Emily M. Zeybek, Burak Tymon-Rosario, Joan Santin, Alessandro D. Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer |
| title | Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer |
| title_full | Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer |
| title_fullStr | Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer |
| title_full_unstemmed | Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer |
| title_short | Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer |
| title_sort | sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer |
| topic | Research Perspective |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640901/ https://www.ncbi.nlm.nih.gov/pubmed/33195736 http://dx.doi.org/10.18632/oncoscience.514 |
| work_keys_str_mv | AT websteremilym sacituzumabgovitecanapromisingantibodydrugconjugateforthetreatmentofpoorlydifferentiatedendometrialcancer AT zeybekburak sacituzumabgovitecanapromisingantibodydrugconjugateforthetreatmentofpoorlydifferentiatedendometrialcancer AT tymonrosariojoan sacituzumabgovitecanapromisingantibodydrugconjugateforthetreatmentofpoorlydifferentiatedendometrialcancer AT santinalessandrod sacituzumabgovitecanapromisingantibodydrugconjugateforthetreatmentofpoorlydifferentiatedendometrialcancer |